Form 4: Medpace Director Sells 6,472 Shares After Exercise

Director Robert O. Kraft exercised options at $54.99 and sold 6,472 shares at a $591.85 weighted average on November 14, 2025, leaving 833 shares owned.

Summary

• On 11/14/2025, Director Robert O. Kraft exercised stock options for 6,472 shares at an exercise price of $54.99 (transaction code M).
• On the same day, 6,472 shares were sold (transaction code S) at a weighted average price of $591.85, with trades ranging from $588.98 to $596.543.
• Post-transactions, direct beneficial ownership stands at 833 common shares.
• The option exercised relates to a grant that vested in full on 05/14/2020 and had an expiration date of 05/17/2026.
• No derivative securities remain beneficially owned after the reported transactions.
• Form filed by one reporting person; role indicated as Director; no 10b5-1(c) plan was indicated.

Sentiment

Score: 4

Explanation: A sizable insider sale reduces direct holdings to 833 shares; however, it was paired with an option exercise and appears to be a routine liquidity event with detailed price transparency.

Positives

• Transparent disclosure of same-day option exercise and sale, including weighted average price and exact price range ($588.98–$596.543).
• Significant value realization relative to the $54.99 exercise price, indicating strong in-the-money options.
• Residual direct ownership remains (833 shares), aligning interests with shareholders.
• No remaining derivative overhang from the exercised option (0 derivative securities post-transaction).

Negatives

• Net reduction in insider shareholding, with only 833 shares remaining after the sale.
• No Rule 10b5-1(c) trading plan indicated, suggesting the sale may have been discretionary.

Future Outlook

No forward-looking statements were provided.

Industry Context

Insider sales following option exercises are common across contract research organizations; such transactions do not inherently signal operational changes. Comparable CROs like IQVIA and ICON also see routine director and executive trading around vesting and option life cycles.

Comparison to Industry Standards

• Insider exercise-and-sell on vesting or ahead of expiration is standard practice across CRO peers (IQVIA: IQV, ICON: ICLR) and broader healthcare services.
• Absence of a 10b5-1 plan is not atypical, though many large-cap peers increasingly use plans for trading predictability and optics.
• Retention of a residual share position (833 shares) is modest relative to customary director holdings at peers, but individual holding levels vary widely.

Stakeholder Impact

• Signals insider monetization at a materially higher market price than the option strike, which some investors may view cautiously.
• Limited direct impact on float and liquidity given the relatively small number of shares versus Medpace’s market capitalization.
• Eliminates derivative overhang from the exercised option, simplifying the insider’s equity profile.

Key Dates

Keywords

insider transaction, Medpace, MEDP, Form 4, stock option exercise, insider sale, beneficial ownership, CRO, biopharma services, Robert O. Kraft